

In the line 495, you explain the limitation of the MSCs-derived exosome treatment.

Please explain a little more about the challenges of the MSCs-derived exosome treatment, for example, in the context of the safety of this treatment.

*Although there is growing interest in the use of MSCs-derived EVs as therapeutic tool for COVID-19 patients, significant challenges still exist, some of which are shared with their parent cells, such as the variability in tissue of origin and donors from which the cells are isolated. Other major challenges concern the establishment of the optimal administration route and the optimal therapeutic dose of EVs, the need to establish a scalable manufacturing GMP process, being in mind that this should follow the same strict scientific, ethical, and regulatory guidelines that apply to MSCs for guaranteeing their safety and efficacy. All these concepts have been better argued under the line 495 in the “Conclusions” section.*